Business Context and Reporting Period
This Form 8-K was filed by Tarsus Pharmaceuticals, Inc. on January 5, 2023, reporting a material definitive agreement entered into on the same date. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Debt
The filing details amendments to a Loan and Security Agreement with Hercules Capital, Inc. and Silicon Valley Bank. Key terms include:
- Total Facility: Up to $175.0 million available in five tranches.
- Expired Amount: $20.0 million from the first tranche expired undrawn on December 15, 2022.
- Second Tranche: $25.0 million availability extended to March 15, 2024, contingent on regulatory milestones.
- Third Tranche: $35.0 million available upon FDA approval of TP-03 for Demodex blepharitis, with a draw deadline of March 15, 2024.
- Interest Rate: Reduced to the greater of (a) Prime Rate + 4.45% (capped at 11.45%) or (b) 8.45%.
- Fees: No lender fees were incurred for this amendment.
The filing does not provide current revenue, profit, cash flow, or total liquidity figures.
Material Changes
Compared to the original February 2, 2022 agreement, the First Amendment introduces the following changes:
- Extended the draw-down deadline for the Second Tranche by one year (from March 15, 2023, to March 15, 2024).
- Established mandatory draw requirements for the Second Tranche: at least $5.0 million by March 15, 2023, and an additional $5.0 million by September 15, 2023.
- Reduced the interest rate calculation formula.
- Amended prepayment terms.
Outlook, Risks, and Contingencies
Future funding availability is contingent on specific milestones:
- Regulatory Milestone: The Second Tranche extension is subject to the achievement of a regulatory milestone, which the Company states was achieved.
- FDA Approval: The $35.0 million Third Tranche is contingent on FDA approval of TP-03 for the treatment of Demodex blepharitis.
- Draw Deadlines: Failure to meet the mandatory draw dates for the Second Tranche may impact the availability of the remaining $15.0 million of that tranche.
Investor Verification Checklist
- Verify the status of the regulatory milestone required for the Second Tranche extension.
- Monitor the FDA review timeline for TP-03 to assess the likelihood of accessing the $35.0 million Third Tranche.
- Confirm the Company's ability to meet the mandatory $5.0 million draw deadlines in March and September 2023.
- Review the full text of the First Amendment (to be filed as an exhibit to the Q1 2023 Form 10-Q) for detailed prepayment terms.